Anixa Biosciences (ANIX) Stock Price, News & Analysis

Company Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Key Stats

• Today's Range: $2.36 to $2.64
• 50-Day Range: $2.13 to $3.33
• 52-Week Range: $2.07 to $5.13
• Volume: 145,153 shs
• Average Volume: 88,561 shs
• Market Capitalization: $77.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Anixa Biosciences Stock Analysis - MarketRank™

Anixa Biosciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 417th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Anixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Anixa Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Anixa Biosciences is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anixa Biosciences is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anixa Biosciences has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.10% of the float of Anixa Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Anixa Biosciences has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anixa Biosciences has recently increased by 4.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anixa Biosciences does not currently pay a dividend.

Dividend Growth

Anixa Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.10% of the float of Anixa Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Anixa Biosciences has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anixa Biosciences has recently increased by 4.15%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.19

News Sentiment

Anixa Biosciences has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $141,561.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 29.13% of the stock of Anixa Biosciences is held by institutions.

ANIX Stock Analysis - Frequently Asked Questions

How have ANIX shares performed this year?

Anixa Biosciences' stock was trading at $2.32 at the start of the year. Since then, ANIX stock has increased by 3.9% and is now trading at $2.41.
View the best growth stocks for 2025 here.

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) issued its quarterly earnings results on Friday, January, 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02.

Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' top institutional investors include International Assets Investment Management LLC (0.03%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani.
View institutional ownership trends.

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Anixa Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 1/10/2025
• Today: 1/18/2025
• Next Earnings (Estimated): 3/21/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANIX
• CUSIP: N/A
• CIK: 715446
• Web: www.anixa.com
• Phone: (408) 708-9808
• Fax: 631-549-5974
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $10.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +252.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,810,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.79%
• Return on Assets: -50.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.31
• Quick Ratio: 11.31

Sales & Book Value

• Annual Sales: $210,000.00
• Price / Sales: 369.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.75 per share
• Price / Book: 3.21

Miscellaneous

• Outstanding Shares: 32,180,000
• Free Float: 24,907,000
• Market Cap: $77.55 million
• Optionable: Optionable
• Beta: 0.90